Method and compositions for treating hepatocellular cancer
AssigneeThe Regents of the University of California
InventorsJames S. Economou, Lisa H. Butterfield, Antoni Ribas Bruguera
Life of this patent
Estimating the term…
Abstract
A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface. The method comprises creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule, where the immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against the cancer cells, and where the part of the alpha fetoprotein molecule is selected from the group consisting of residues 137-145 of SEQ ID NO:2, and residues 325-334 of SEQ ID NO:2 and a combination of the preceeding.
Claims21
A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule;
- where the immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against the cancer cells;
- and
- where the part of the alpha fetoprotein molecule is selected from the group consisting of residues 137-145 of SEQ ID NO:2, and residues 325-334 of SEQ ID NO:2 and a combination of the preceeding.
A method for preventing or for treating hepatocellular carcinoma in a human, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of activating alpha fetoprotein cytotoxic T lymphocytes against the cancer cells to at least part of the amino acid sequence of SEQ ID NO:2 by administering to the human one or more than one peptide selected from the group consisting of residues 137-145 of SEQ ID NO:2, and residues 325-334 of SEQ ID NO:2.
A method for preventing or for treating hepatocellular carcinoma in a human, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface, the method comprising the step of activating alpha fetoprotein cytotoxic T lymphocytes against the cancer cells to at least part of the amino acid sequence of SEQ ID NO:2 by administering to the human one or more than one composition including dendritic cells pulsed with one or more than one peptide that forms at least part of the amino acid sequence of SEQ ID NO:2;
- and
- where the one or more than one peptide is selected from the dendritic cells pulsed with one or more than one peptide is selected from the group consisting of residues 137-145 of SEQ ID NO:2, and residues 325-334 of SEQ ID NO:2.
An isolated peptide useful for preventing or for treating cancer selected from the group consisting of residues 137-145 of SEQ ID NO:2, and residues 325-334 of SEQ ID NO:2.
Means for preventing or for treating cancer comprising one or more than one peptide selected from the group consisting of residues 137-145 of SEQ ID NO:2, and residues 325-334 of SEQ ID NO:2.
Dependencies are inferred from the claim text.